Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The company is currently trialing the drug candidate for obesity and type 2 diabetes
It is assayed for endotoxin by LAL (Limulus Amebocyte Lysate, typically 1 EU/mg) and supplied with a per-lot Certificate of Analysis
Importantly, this was not driven by aggressive rebate engineering
Below is a list of products that will require prior authorization starting April 1 st , 2026
Gastric Emptying Modulation GLP2 transiently delays gastric emptying, similar to selective GLP-1 receptor agonists: Slowed rate of nutrient absorption from the gastrointestinal tract Reduced postprandial glucose excursions Effect is most pronounced after initial doses and diminishes with continued treatment Contributes to improved glycemic control through multiple complementary mechanisms Central Nervous System Effects Appetite Regulation Both GIP and GLP-1 receptors are expressed in brain regions controlling appetite and food intake: Reduced food intake and appetite through central nervous system receptor activation Promotion of satiety signals leading to decreased caloric consumption Potential modulation of reward-related feeding behaviors Weight loss effects that appear mediated through both homeostatic and hedonic feeding pathways Clinical trials have demonstrated substantial weight reduction, with participants experiencing decreased appetite as a commonly reported effect of GLP2 treatment
US$ 22.22
US$ 27.02
US$ 28.22
US$ 25.21
